Incidence of carbapenemase-resistant isolates of Klebsiella pneumoniae in a regional hospital in Slovakia; contribution of virulence genes and biofilm production to overall pathogenicity Authors: Jaroslava Dekkerová, Tomáš Walentín, Anna Jozefíková, Jana Liščáková, Helena Bujdáková Published: 2026 ABSTRACT AbstractBackgroundThe prevalence of carbapenemase (CPE)-producing K. pneumoniae isolates has increased in hospitals worldwide over the past decade. Resistance is often associated with the ability of clinical isolates to form biofilm. The main objective was to investigate biofilm development in 30 hospital isolates of K. pneumoniae with confirmed CPE production as well as to analyze the distribution of resistance genes, the frequency of virulence genes, and their role in the regulation of biofilm.MethodsSelected isolates of K. pneumoniae with CPE production were examined for their ability to form biofilms using crystal violet staining. The presence of resistance genes (blaSHV1, blaTEM1, blaCTXM1) and genes (fimH, mrkD, entB) associated with biofilm formation was confirmed by PCR. Quantitative real-time PCR was then performed to compare the expression of biofilm-associated genes in weak, moderate and strong biofilm formers among K. pneumoniae.ResultsMore than 50% of all K. pneumoniae isolates were confirmed to be strong biofilm producers. PCR confirmed the presence of resistance-associated genes and genes important for biofilm development in all clinical isolates tested. Additionally, qPCR showed increased regulation of the adhesion-related genes fimH and mrkD in moderate or strong biofilm formers of K. pneumoniae compared to weak biofilm formers.ConclusionsThe present results provide valuable information on the relationship between increased CPE resistance, biofilm production, and its genetic regulation in K. pneumoniae hospital isolates.Keywords: Biofilm, Klebsiella pneumoniae, Resistance, Virulence Introduction Klebsiella pneumoniae is responsible for about 10% of nosocomial bacterial infections and belongs to the most common pathogens isolated in intensive care units (ICUs) [[1], [2], [3], [4]]. The World Health Organization (WHO) lists K. pneumoniae as one of the highest priority bacteria to develop new antibiotics due to the global increase in antibiotic resistance [5]. K. pneumoniae isolates can acquire various mechanisms of antibiotic resistance, including ESBL production, plasmid-encoded AmpC-β- lactamases and class A, B and D carbapenemases [6]. K. pneumoniae is considered the most common carbapenemase-producing (CPE) Enterobacteriaceae with production of Verona integron-encoded metallo-beta-lactamase (VIM), IMP-type metallo-beta-lactamase (IMP), the New Delhi metallo-beta-lactamases (e.g. NDM-1) and OXA-48-like carbapenem-hydrolyzing oxacillinases, which are considered the most frequent carbaenemases in Europe [[7], [8], [9]]. The rapid and global expansion of CPE is a threat to healthcare and patient safety worldwide, as it seriously curtails the ability to cure infections. Infections due to CPE are associated with higher in-hospital mortality [8,10]. The incidence of CPE-positive K. pneumoniae is rapidly increasing. In Europe they are responsible for more than 50% of nosocomial infections [3,11,12]. The mortality rate for carbapenem-resistant Klebsiella pneumoniae (CRKP)| is high, with studies reporting 28-day all-cause mortality rates between 33.8% and 42.1%. Additionally, patients with CRKP bloodstream infections have a higher mortality rate compared to those with carbapenem-susceptible K. pneumoniae infections [13,14]. CPE K. pneumoniae strains frequently form biofilms, an important virulence factor related to hospital associated infections, which further complicates the treatment by enhancing bacterial persistence and reducing the efficacy of antimicrobial therapy [15]. It has been reported that the majority of clinically isolated K. pneumoniae are strong or moderate biofilm formers [16]. The biofilm of K. pneumoniae is controlled by many factors. Although kinetic of biofilm formation differ among strains, the process is similar and includes adhesion to the surface, microcolony formation, maturation, and dispersion [17]. It has been estimated that the resistance of bacterial biofilms to antimicrobial agents can be up to 1000-times higher than that of planktonic bacteria [18]. In addition, the bacteria in biofilm communities are often in close proximity, which increases gene transfer between bacterial cells and facilitates the spread of drug resistance genes [19]. The mechanism of biofilm development is genetically regulated. The virulence genes fimH, mrkD, and entB are important for the biofilm development of K. pneumoniae [20]. The fimH gene encodes the small subunit FimH of type 1 fimbriae. It is important for bacterial adhesion in the initial phase of biofilm development; the mrkD gene is coding for the adhesin MrkD, which is located at the tip of type 3 fimbriae and is important for both adhesion and invasion of K. pneumoniae. The entB gene encodes enterobactin – an important siderophore involved in invasion [20]. In this study, epidemiological data were collected, and virulence factors were analyzed among clinical K. pneumoniae isolates obtained during one-year period in a regional hospital serving approximately 126 000 residents. In the past five years, only two studies have addressed surveillance of K. pneumoniae resistance in Slovakia [21,22]. According to these and other European studies, the incidence of CPE- or ESBL-positive K. pneumoniae isolates has increased rapidly [5,12]. In addition, this study analyzed the distribution of resistance genes, the frequency of virulence genes, and their role in regulating biofilm abundance among CPE-positive K. pneumoniae hospital isolates. Material and methods Characterization of reference strain and clinical isolates The reference strain K. pneumoniae CCM4985 (CCM4985 corresponding to K. pneumoniae ATCC 70060, Czech Culture Collection, Brno, Czech Republic) and 30 clinical isolates from regional hospital in northern Slovakia (Regional hospital in Kysuce, Department of Clinical Microbiology, Čadca, Slovakia) collected between October 2023 and January 2024 were used for this study. The resistance profile of the clinical isolates was established by determining minimal inhibitory concentration of antibiotics using MIDITECH colorimetric susceptibility test (Bel-MIDITECH s.r.o., Slovakia). Clinical isolates were divided as Multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR). MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) and PDR was defined as non-susceptibility to all agents in all antimicrobial categories. Bacterial identification was done by MALDI-TOF Biotyper (Bruker Daltonik, Germany). Tested clinical isolates were confirmed as CPE producing K. pneumoniae except of isolates of number 5, 6 and 27 by rapid test for the detection of carbapenemases KPC, OXA-48, VIM, IMP and NDM (NG TEST®/CARBA-5 NG Biotech, France). The reference strain K. pneumoniae was re-identified on CHROMagar™ ESBL (CHROMagar, France) (Supplementary material, Fig. S1.) and the susceptibility to selected antibiotics was determined using disk diffusion test according to EUCAST [23]. A detailed protocol for identification and disk diffusion test is described in Supplementary material. All strains were stored in 25% (v/v) glycerol and 60% (v/v) Mueller Hinton Broth (MHB, BioLife, Italy) at −80 °C. Quantification of biofilm and metabolic activity of biofilm First, the ability of the reference strain K. pneumoniae CCM4985 and clinical isolates of K. pneumoniae to form biofilms was tested. To produce biofilm, overnight cultures prepared in MHB (37 °C, 18 h) were inoculated into MHB supplemented with 2 % (w/v) glucose and incubated at 37 °C on a shaker (150 rpm). Subsequently, 100 μL of the bacterial suspension from the exponential phase (after 2.5 h of cultivation; OD600 = 0.5). was inoculated in 96-well microtiter plates (Sarstedt, Germany). The wells were filled with 100 μL of fresh MHB +2 % glucose (CentralChem, Slovak Republic). The plates were incubated statically at 37 °C for 48 h to develop a biofilm. The biofilm was quantified by crystal violet (CV) staining assay, and the metabolic activity of the biofilm was determined by MTT assay to evaluate the viability of bacteria in biofilms according to the protocol described by Traba and Liang [24]. with minor modifications; biofilms were incubated with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) (0.5 mg ml−1) at 37 °C for 15 min. After washing, the purple formazan formed inside the bacterial cells was dissolved by MTT detergent: 1.5% (w/v) HCl mixed in Isopropanol. Plates were incubated in dark at 37 °C for 15 min and measured by microplate reader. The quantity of biofilm was determined by CV staining. Briefly; biofilms in 96 well plates were stained with 0.1% (w/v) CV (Centralchem, Slovakia) for 15 min. The excess dye was removed by thoroughly rinsing the plate with water and PBS. CV dye associated with biofilms was then extracted by 96% ethanol and quantified using a microplate reader. The quantity and metabolic activity of biofilms were measured at OD570 using a microplate reader (Glomax, Promega, USA). Each experiment was performed twice, and the results were calculated as the mean ± standard deviation (SD) from at least five parallel wells. The results of quantification of biofilms were expressed according to the criteria of Stepanović et al. [25]. Detection of resistance and virulence genes and phenotypic confirmation of ESBL resistance The presence of virulence genes (fimH, mrkD and entB) and resistance genes (blaCTXM1, blaTEM1 and blaSHV1) in reference strain and clinical isolates of K. pneumoniae was determined by PCR according to protocol described by Ballén et al. [20]. Briefly, a single colony from an overnight culture plate was suspended in 100 μL of sterilized distilled water. The suspension was boiled for 10 min and centrifuged for 10 min at 12000 g. The supernatant was used as the DNA template. Polymerase chain reaction (PCR) was used to detect various virulence genes encoding fimbriae (fimH, mrkD) and siderophores (entB). ESBL-associated genes (blaSHV1, blaTEM1, blaCTXM1) conferring resistance were detected as well. PCR conditions and composition of PCR mix, cycle conditions and list of primers used in this study are listed in Supplementary data. Additionally, ESBL resistance was tested by phenotypical method according to EUCAST (2019) by combined disk diffusion assay. Protocol and result interpretation are listed in Supplementary data. Isolation of RNA and qPCR analysis of virulence genes coding for fimH, mrkD and entB in selected clinical isolates RNA was isolated from the biofilm of selected clinical isolates of K. pneumoniae according to their ability to form biofilms; K. pneumoniae 27 (weak biofilm former), K. pneumoniae CCM4985, K. pneumoniae 32 (both moderate biofilm former) and K. pneumoniae 33 (strong biofilm former). Briefly, the RNA was isolated from 24-h biofilms of K. pneumoniae prepared as previously described. RNA was extracted from scraped biofilm cells according to the manufacturer's recommendations of the GeneJET RNA Purification Kit (Thermo Scientific, USA). The extracted RNA was treated with DNase (DNase1; Sigma-Aldrich, Germany). The cDNA synthesis was performed using a Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific, USA) according to the manufacturer's instructions. Synthesized cDNA was used directly for qPCR. For quantitative real-time PCR (qPCR), the primer set for the fimH, mrkD and entB genes listed in Table 1 (Supplementary material) were used. The gene recA was used as housekeeping gene [26]. All primers were synthesized by Metabion International AG (Planegg/Steinkirchen, Germany). HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis BioDyne OÜ, Estonia) and Mx3000P qPCR system (Agilent Technologies, Inc., USA) were used for qPCR. A thermal protocol for qPCR was established according to the manufacturer's instructions. Data was analyzed using the MxPro software Agilent Technologies. Relative gene expression was calculated according to the 2ΔΔCT method [27]. The values for the weak biofilm former K. pneumoniae 27 were set as controls and normalized to 1. Data was collected from at least three qPCR assays with three parallel samples at each measurement. The normality of the data was determined by the Shapiro–Wilk test and analysis of relative gene expression was completed with one-way ANOVA in statistic software calculator Statistic Kingdom (https://www.statskingdom.com/index.html). Differences were considered significant at p < 0.05 (∗). Results and discussion Prevalence of K. pneumoniae isolates in Slovakia among years 2019-2023 and their virulence profile The prevalence of pathogenic K. pneumoniae in the population has increased in recent decades [6,28]. K. pneumoniae is the main cause of infections initiated by carbapenem-resistant bacteria worldwide and, with a prevalence of 11.7% in acute-care hospitals, ranked second among isolated bacteria in a recent assessment of healthcare-associated infections (HAIs) in Europe [29,30]. HAIs are commonly associated with the rapid spread of antibiotic resistance among clinical isolates and more than 80% of clinical isolates are often resistant to multiple antibiotics [30]. Multidrug resistance in K. pneumoniae is associated with increased production of CPE and ESBL [5,6]. According to available data from the regional hospital, there is a higher prevalence of CPE-positive K. pneumoniae bloodstream infections in the ICU and Ward. In addition, 30 % of CPE-positive K. pneumoniae bloodstream isolates monitored in the hospital over past five years were isolated in the ICU (Fig. 1). The ICU is generally a higher risk environment for the spread of life-threatening K. pneumoniae [31,32]. In the study of Cristea et al., data showed a 20% higher incidence of multidrug resistance (MDR) in K. pneumoniae isolates from the ICU compared to surgical wards, which is consistent with our data [32]. A work of Xiaohua et al. found that 54% of K. pneumoniae isolates from the ICU were CPE-positive, while only 8% were non-resistant K. pneumoniae [31]. The hospital environment generally carries a high risk for rapid nosocomial spread of K. pneumoniae, confirming that CPE-positive K. pneumoniae isolates have the highest transmissibility [33]. Prevalence (in percent) of CPE-positive and CPE-negative K. pneumoniae hospital isolates in wards and ICU over 5 years (2019 – 2023). Overall distribution of K. pneumoniae in the ward and ICU of regional hospital in Slovakia and comparison of CPE-positive and negative K. pneumoniae numbers (table) among clinical isolates. Over the past 5 years, the rate of resistance of K. pneumoniae to common antibiotics has increased and the U. S. Center for Disease Control and Prevention declared carbapenem-resistant Enterobacteriaceae an urgent threat to public health in the United States, with K. pneumoniae accounting for approximately 80% of cases [29]. The prevalence of CPE-positive K. pneumoniae bloodstream isolates in Slovakia has also increased (Fig. 2). Overall prevalence of CPE producing K. pneumoniae among bloodstream isolates in Slovakia between the years 2012 – 2024. In summary, data from the Slovakian National Antimicrobial Resistance Surveillance System (SNARS) for 2013 to 2024 indicate that the occurrence of CPE-positive K. pneumoniae in blood cultures in Slovakia shows an overall increasing trend (Fig. 2). During this 10-year period, the prevalence of CPE-positive K. pneumoniae increased from 5.49% in 2013 to 28.04% in 2024 indicating a rapid spread of CPE-positive K. pneumoniae in regional hospital in Slovakia. The increasing trend in the prevalence of CPE-positive K. pneumoniae in Slovakia has also been confirmed by the European Center for Disease Prevention and Control (ECDC) [28]. However, the prevalence of CPE-positive K. pneumoniae over the past decade is serious problem worldwide, especially in hospital environments [3,28,30,[34], [35], [36]]. Recently, Lin et al. published systematic review and meta-analysis on the prevalence of hospital-acquired CPE-positive K. pneumoniae infections from 14 countries. The global prevalence of CPE-positive K. pneumoniae among patients with K. pneumoniae infections was almost 30% and varied among geographical regions. South Asia had the highest CRKP prevalence at 66.04%, while high-income North America had the lowest prevalence at 14.29% [35]. Resistance and virulence profile of K. pneumoniae isolates The thirty CPE-suspected K. pneumoniae isolates were used in further experiments to analyze their resistance and virulence profile. The origin of the samples varied among isolates. Most K. pneumoniae isolates (47%) were obtained from the larynx or sputum of patients. The second most common site of isolation was urine, where 37% of K. pneumoniae isolates were identified (Fig. 3). In the report of Al Hasan et al., the most common origin of K. pneumoniae was urine in 41% of cases followed by the gastrointestinal tract (24%), respiratory tract (10%), and other (2%) [37]. Similar to our data, Zar et al. showed that the respiratory tract is also frequently a source of K. pneumoniae. In their study 14.3% of lower respiratory tract infections in children were caused by K. pneumoniae [38]. On the other hand, K. pneumoniae infections are more common in the elderly, who are much more susceptible to complications in the treatment of chronic infections. In the study of Wang et al., almost 65% of patients with K. pneumoniae infection were older than 60 years. The lower respiratory tract was the main infection site, accounting for 71% [39]. Origin of the clinical K. pneumoniae isolates used in this study. The resistance profile of the samples was analyzed based on data from antimicrobial susceptibility testing. The presence of CPE was confirmed in 93 % (n = 28) of all isolates. The presence of CPE was not detected in two K. pneumoniae isolates (5 and 27), but all clinical isolates were resistant to ertapenem. Resistance to meropenem was found in 67% of isolates (n = 20). All clinical isolates were resistant to penicillin, cephalosporines, trimethoprim + sulfamethoxazole, and gentamicin. Overall, antimicrobial resistance in K. pneumoniae can be classified as multidrug-resistant (MDR), extensively drug-resistant (XDR), or pan-drug-resistant (PDR) based on the number of antibiotic classes, in which the bacteria are resistant. Among all clinical isolates (n = 30), 40% were confirmed as multidrug resistant (n = 12) and 60% as extensively drug-resistant (n = 18). None of the isolates were pandrug-resistant. Similarly, Asri et al. reported a high proportion of MDR K. pneumoniae in recent meta-analysis. Based on studies from 28 countries across six regions, this meta-analysis estimated the pooled prevalence of nosocomial MDR K. pneumoniae at 32.8% (95% CI, 23.6–43.6) [34]. Detailed data on sample origin and resistance profiles are summarized in Fig. 4. The complex analyses of the clinical isolates of K. pneumoniae used in this study include the origin of the isolates, confirmation of CPE, antibiotic susceptibility profile and presence of virulence genes (fimH, mrkD, entB) and ESBL resistance genes (blaSHV1, blaCTXM1, blaTEM1) detected by PCR. The virulence profile was analyzed by testing the ability of CPE-positive K. pneumoniae clinical isolates to form biofilm. The ability of bacteria to form biofilms may be associated with increased prevalence in the hospital environment and the multidrug resistance phenomenon in K. pneumoniae [15,40]. In the study of Nirwati et al., the overall proportion of multidrug-resistant K. pneumoniae isolates was 54.49% and 85% of these isolates were biofilm producers, with 27% classified as strong and 28% as moderate biofilm producers [41]. In our study, 57% of clinical isolates of K. pneumoniae were capable of forming a strong biofilm (n = 17) followed by 40 % of moderate biofilm formers (n = 12) and 3% classified as weak biofilm formers (n = 1) (Fig. 5). Biofilm was quantified by staining with crystal violet (CV) and metabolic activity within biofilms was determined by the MTT reduction assay. The CV staining method quantifies total biomass within biofilms (live/dead cells, matrix, proteins), while the MTT assay does not stain polysaccharides, DNA, proteins, and other biological molecules. Only live bacteria in the biofilms are counted in the MTT assay by measuring the metabolic activity of each individual bacterial cell [24]. The biofilm viability assay is a very important parameter in complex analyses of the biofilm properties of tested K. pneumoniae clinical isolates. Higher number of metabolically active or live cells within biofilms are potentially able to disperse from the biofilm and colonize another part of the body or tissue [42]. Additionally, during period of high metabolic activity, some bacteria may upregulate the production of other virulence factors, such as toxins, which further increase their ability to cause disease and invade host tissues [43]. Our results showed that strains with high metabolic activity in biofilm cells are mostly strong biofilm formers (Supplementary material; Fig. S3, Fig. S4) Interestingly, the isolate K. pneumoniae 33, which had the highest biofilm activity, was multidrug resistant and CPE-positive. In contrast, isolate with the lowest biofilm and metabolic activity (K. pneumoniae 27) was neither MDR nor a CPE producer. Biofilm characteristics of clinical K. pneumoniae isolates and correlation between sample origin and biofilm abundance. In summary, we confirmed that strong biofilm producers were the most metabolically active and we can hypothesize that they may be potentially more virulent or more easily disperse and colonize other surfaces or tissues. Interestingly, the majority of strong biofilm formers in our study were isolated from the larynx and sputum, followed by urine. In contrast, urine was the most frequent source of the isolation of moderate biofilm formers. The clinical isolate K. pneumoniae 33 from a wound had the highest biofilm activity of all samples. However, the ability of K. pneumoniae to form a biofilm is strain-dependent and the site of isolation of clinical specimens does not affect the strength of biofilm. In the study of Di Domenico et al., the distribution of strong and moderate biofilm formers was almost equal among K. pneumoniae isolates, but the level of biofilm was not significantly related to the site of isolation [44]. The presence of virulence and resistance genes in K. pneumoniae and their contribution to biofilm production The ability of bacteria to form biofilms is genetically regulated by the expression of virulence-associated genes, such as fimH, mrkD or entB [20]. The results showed that the genes encoding adhesins were present in the tested isolates (Supplementary material; Fig. S5). These findings are consistent with the study of Ballen et al., in which almost all clinical isolates of K. pneumoniae possessed virulence genes and isolates lacking the tested genes were classified as weak biofilm formers [20]. Similarly, in the study of Horvath et al., 90% of the clinical isolates of K. pneumoniae contained all virulence associated genes. This study demonstrated a high frequency of virulence factors in CPE-producing K. pneumoniae that were strong biofilm formers [45]. In addition, qPCR was performed to show the relative changes in the expression of the tested genes. The qPCR revealed different expression levels of the fimH, entB and mrkD genes in selected representatives of weak biofilm producers (K. pneumoniae 27), moderate biofilm producers (K. pneumoniae CCM4985), and strong biofilm producers (K. pneumoniae 33). The relative changes in the expression of the tested genes are shown in Fig. 6. These results confirmed the up-regulation of the fimH, entB and mrkD genes during biofilm development of K. pneumoniae. The relative expression of these genes varied depending on the ability of the isolates to form biofilm. The strong biofilm former (K. pneumoniae 33) showed higher expression of the fimH and mrkD genes, but only basal expression of the entB gene compared to the weak biofilm former (K. pneumoniae 27), expression of which was set to 1. Statistical analyses were performed as follows. The Shapiro-Wilk test showed that the data were normally distributed and a subsequent one-way ANOVA test confirmed significant changes in the distribution of the biofilm-associated genes fim H (p=0.024) and mrk D (p=0.003) among strong and moderate biofilm formers compared to weak biofilm formers. Statistical analysis did not confirm significant changes in entB gene (p=0.05) among isolates related to their ability to form biofilm. The presented results indicate that the expression of the fimH and mrkD genes directly influenced the abundance of K. pneumoniae biofilm. Biofilm formation mediated by MrkD is crucial for the ability of K. pneumoniae to adhere to a substrate and form a biofilm as the deletion mutants in the mrkF and mrkD genes did not form a biofilm [46]. Quantitative real time PCR of biofilm related genes of K. pneumoniae. Comparison of the relative change in gene expression of fimH, mrkD and entB genes in weak biofilm former (K. pneumoniae 27), moderate biofilm formers (K. pneumoniae CCM4985; K. pneumoniae 32) and strong biofilm former (K. pneumoniae 33). The second objective was to analyze the frequency of resistance genes blaSHV1, blaCTXM1 and blaTEM1 in clinical isolates of K. pneumoniae. Antimicrobial resistance together with biofilm formation are key factors of virulence of K. pneumoniae isolated from hospital. In addition to prior confirmation of CPE mediated resistance of the tested clinical isolates, we analyzed the frequency of ESBL mediated resistance genes due to high prevalence of the MDR phenomenon among our clinical samples. The presence of genes for the respective ESBL varied among isolates (Supplementary material; Fig. S6); blaSHV1 (100%) was the most frequent, followed by blaCTXM1 (97%). The blaTEM1 gene was confirmed in 87% of the isolates (n = 27). ESBL resistance among clinical isolates was confirmed by phenotypic method as well (Supplementary material; Table 4, Fig. S2). Phenotypic confirmation was in accordance with data from PCR, all strains that carried genes blaCTXM1 (ESBL related gene in K. pneumoniae) and blaSHV1 as well have been confirmed as ESBL producers by phenotype method as well. Our hypothesis is that the presence of the blaSHV1 gene in all confirmed ESBL K. pneumoniae might suggest its possible mutation (like at Gly238 or Glu240), which turn of Beta lactamase SHV1 into an Extended-Spectrum Beta-Lactamase (ESBL) SHV of different type [47]. In general, contribution of ESBL-related genes among K. pneumoniae is very common [[46], [47], [48]]. However, other ESBL-encoding genes that were not examined in this study, might be also presented in tested clinical isolates and individual isolates may harbor multiple resistance genes simultaneously. The limitation of our results should be detection of only three types of ESB- related genes, specifically blaSHV1, blaTEM1 and blaCTXM1. We focus the study on detection of those genes due to their highest frequency of incidence in clinical isolates of K. pneumoniae. Like our data, the study of Dehshiri et al. confirmed the blaSHV1 gene as the most frequently identified ESBL gene in clinical isolates of K. pneumoniae from urinary tract infection, followed by the blaCTXM1 gene [46]. In contrast, in the study of El Hariri et al. the most prevalent gene was blaTEM1 (25%), followed by blaCTXM1 (19.08%) and blaSHV1 (16.45%) [48]. On the other hand, in the study of Ugbo et al., the most prevalent ESBL genotypes among the ESBL-producing K. pneumoniae clinical isolates were blaCTXM and blaTEM [49]. The study of Ballen et al. also confirmed the distribution of ESBL genes among almost all K. pneumoniae clinical isolates identified strong biofilm formers, suggesting that ESBL resistance is also problematic in biofilm-producing strains [20]. In summary, the key scientific contribution of this study is to highlight not only the high prevalence of ESBL resistance among K. pneumoniae isolates with confirmed CP production, but also to emphasize the strong biofilm-forming abilities of these clinical isolates. More than 50% of all samples were confirmed as strong biofilm producers, which is important for understanding the complex clinical picture of K. pneumoniae and its transmission in population. The ability to form biofilm and colonize medical devices and hospital environments is crucial for the virulence potential of K. pneumoniae. Our study confirmed that the genetic regulation of biofilm development is related to the amount of biofilm produced, suggesting that targeting this regulation could be a promising direction for future research. On the other hand, this study is likely limited by the small sample collection, but all samples are confirmed to be MDR or XDR indicating a high prevalence of resistance in the nosocomial environment among K. pneumoniae. We can expect an increasing trend not only in Slovakia but also worldwide. Conclusions This study provided a comprehensive analysis of the distribution, resistance and virulence profiles of clinical isolates from selected regional hospital in northern Slovakia. The results confirmed a high incidence of CPE- and ESBL-positive isolates exhibiting the MDR phenomenon. The expression of resistance and biofilm-associated genes indicates a high virulence potential of the tested K. pneumoniae strains. All clinical isolates were capable of forming biofilms, and more than 50% were confirmed as strong biofilm producers. Additionally, strong and moderate biofilm producers showed a significant increase in relative gene expression compared to non-biofilm formers. It is important to note that CPE-positive K. pneumoniae isolates contained at least two types of ESBL associated genes, namely blaSHV1 and blaCTXM1. Transposon mediated resistance in ESBL producing K. pneumoniae is critical, especially in hospitals, and effective measures are necessary to prevent its transmission. The prevalence of CPE-positive K. pneumoniae has increased over the last decade not only in Slovakia but worldwide, making these bacteria leaders in nosocomial spread. Nosocomial infections are often associated with biofilms, and K. pneumoniae appears to be one of the most threatening bacteria in this regard due to their high ability to form life-threatening biofilms. Patient consent statement This study does not include factors necessitating patient consent. Data availability statement The original contributions presented in the study are included in the article/supplementary material; further inquiries can be directed to the corresponding authors. Ethical approval None. Funding This work was funded by the Slovak Research and Development Agency under contracts of no. APVV-21-0302, APVV-22-0150; project VEGA 1/0240/23 supported by the Ministry of Education, Research, Development and Youth of the Slovak Republic, and by EU Next Generation EU through the Recovery and Resilience Plan Slovakia under the project no. 09I01-03-V04-00022. CRediT authorship contribution statement Jaroslava Dekkerová: Conceptualization, Formal analysis, Methodology, Visualization, Writing – original draft, Writing – review & editing. Tomáš Walentín: Formal analysis, Methodology, Writing – review & editing. Anna Jozefíková: Methodology, Validation, Writing – review & editing. Jana Liščáková: Writing – review & editing. Helena Bujdáková: Conceptualization, Funding acquisition, Supervision, Validation, Writing – review & editing. Declaration of competing interest No conflicts of interest to declare. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.nmni.2026.101778. Contributor Information Jaroslava Dekkerová, Email: jaroslava.dekkerova@uniba.sk. Helena Bujdáková, Email: helena.bujdakova@uniba.sk. Supplementary data The following is the Supplementary data to this article. Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement The original contributions presented in the study are included in the article/supplementary material; further inquiries can be directed to the corresponding authors.